Question · asked by 1 review
Degarelix vs standard androgen suppression therapy: Cancer‐specific survival (24 months) (Number of cancer‐related deaths)
- Population
- hormone‐sensitive prostate cancer
- Intervention
- Degarelix
- Comparison
- standard androgen suppression therapy
- Outcome
- Cancer‐specific survival (24 months) (Number of cancer‐related deaths)
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Degarelix vs standard androgen suppression therapy Cancer‐specific survival  · hormone‐sensitive prostate cancer The review found no eligible studies for this question. Degarelix for treating advanced hormone‐sensitive prostate cancer (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.